Idt Australia Limited · ASX:IDT
Idt Australia — BioShares Conference 2015
16 slides from Idt Australia's conference presentation, Jul 20, 2015
Slide 1: Good Medicine
GOOD MEDICINE AjUO SSN [euOSsJed JOS
Slide 2: Safe Harbour
July 2015 BioShares Conf. SAFE HARBOUR For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of IDT Australia Ltd to be ma
Slide 3: IDT Australia Ltd Investment Proposition
IDT AUSTRALIA LTD (ASX.IDT) INVESTMENT PROPOSITION For personal use only The Business: 23 US FDA approved generic drugs near to market Aggregate Addressable Two in-house products, one under FDA review Market US$806m Contract drug development revenues (Boronia, Melbourne) Contract drug manufacturing
Slide 4: A Platform for Rapid Growth
30 YEAR HISTORY A PLATFORM FOR RAPID GROWTH For personal use only IDT Organic Base Business: IDT Generics: Provides revenues and capabilities Leverages facilities and multiplies margins Drug development services Proprietary IDT Generic Drug Portfolio Contract drug manufacture Transformative M&A Cont
Slide 5: World Class Manufacturing Facilities
GLOBALLYAPPROVED WORLD CLASS MANUFACTURING FACILITIES For personal use only SENSITIZING DRUGS ANTI–CANCER DRUGS HORMONES CARBOHYDRATE DRUGS HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB COATING www.idtaus.com.au 5
Slide 6: CMAX Our Clinical Unit
CMAX OUR CLINICAL UNIT For personal use only CMAX clinical trials facility, 21 years old Australia’s oldest, largest, most experienced clinical trials unit 13,000 patient, well categorised database 50 bed clinical unit located at Royal Adelaide Hospital Moving to new purpose built facilities 2016 St
Slide 7: IDT Group Sales Organic Growth
IDT GROUP SALES ORGANIC GROWTH For personal use only 12,000 Revenue, by Half Year ($000) 10,000 8,000 6,000 4,000 18,000 Revenue, Full Year ($000) 16,000 2,000 14,000 0 12,000 FY14 H1 FY14 H2 FY15 H1 FY15 H2 10,000 8,000 6,000 4,000 2,000 0 NB. Based upon unaudited 2015 results FY12 FY13 FY14 FY15 w
Slide 8: Manufacturing Sales Pipeline Growth
MANUFACTURING SALES PIPELINE GROWTH For personal use only Manufacturing Sales Pipeline ($000) 45,000 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 Jun-13 Dec-13 Jun-14 Dec-14 Jun-15 www.idtaus.com.au 8
Slide 9: Effect of Operational Leverage
EFFECT OF OPERATIONAL LEVERAGE For personal use only 60% revenue growth at Melbourne 2014/15, with zero operational expense increase Organic growth + in house product registrations moving forward Program of product acquisitions will drive this harder moving forward Revenue Growth Rate Profit Growth
Slide 10: In-House Product Development Opportunities
IN-HOUSE PRODUCT DEVELOPMENT OPPORTUNITIES For personal use only • Temozolomide – US$300m brain tumour drug – IDT filed ANDA Dec13, now in correspondence with FDA – Target launch window late CY16, early CY17 • Project Teton – $80m oncology/stem cell adjunct product – Development work complete – Dete
Slide 11: Proprietary Generics Market Entry and Opportunities
PROPRIETARY GENERICS MARKET ENTRY AND OPPORTUNITIES For personal use only Products* Target Launch Windows* Addressable Markets Doxazosin CYH1 2016 US$65.6m Flecainide CYH2 2016 US$26.1m Ciprofloxacin CYH2 2016 US$50.2m Clarithromycin CYH2 2016 US$24.0m Nortriptyline CYH1 2016 US$27.8m Prazosin CYH1
Slide 12: Path to Market
PATH TO MARKET For personal use only • These products are sold in the US via tender to pharmacy chains, regional distributors and GPOs • Third party distribution strategy to limit risk • Very strong interest received from 13 potential distribution partners • Currently approaching finalization of fav
Slide 13: Board & Management in Place to Deliver
BOARD & MANAGEMENT IN PLACE TO DELIVER For personal use only MANAGEMENT TEAM BOARD Dr Paul D R MacLeman (CEO & MD) Graeme Kaufman (Chairman) Deb Cailes (Market Access) Dr Paul D R MacLeman (MD) Jane Kelly (Clinical) Geoff Lord (Vice Chairman) Paul Loria (Reg & Quality) Dr Graeme Blackman (NED) Joann
Slide 14: Target 2016 Milestones
TARGET 2016 MILESTONES For personal use only INCREASED ORGANIC SALES INTO PROFITABILITY CONTINUE TO PROGRESS TEMOZOLOMIDE THROUGH FDA MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET PROGRESS WITH RE-COMMERCIALISATION OF US GENERIC PORTFOLIO MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GEN
Slide 15: Contact Us
CONTACT US For personal use only Dr Paul D R MacLeman MANAGING DIRECTOR +61 (0) 3 9801 8888 info@idtaus.com.au www.idtaus.com.au Follow Us on Twitter @IDTAus www.idtaus.com.au 15
Slide 16: Questions and Answers
For personal use only QUESTIONS AND ANSWERS